Phase II STORM Trial: Selinexor + Dexamethasone Is Active in Patients With Heavily Pretreated Refractory MM

December 3-6, 2016; San Diego, California
First-in-class XPO1 inhibitor selinexor, in combination with low-dose dexamethasone, shows encouraging activity in heavily pretreated patients with MM refractory to multiple immunomodulatory agents, proteasome inhibitors, and anti-CD-38 monoclonal antibodies, according to the phase II STORM trial data.
Format: Microsoft PowerPoint (.ppt)
File Size: 1.06 MB
Released: December 6, 2016

Acknowledgements

This activity is supported by educational grants from
Amgen
Celgene Corporation
Incyte
Merck & Co., Inc.
Seattle Genetics

Related Content

From Clinical Care Options (CCO), video featuring expert insights on best practices for nurses within a multidisciplinary CAR T-cell therapy care team

person default Caron A. Jacobson, MD
Program Director
Alix Beaupierre, BSN, RN, OCN person default Kathleen McDermott, RN, BSN, OCN, BMTCN
Registered Nurses: 2.0 Nursing contact hours Released: July 8, 2020 Expired: July 7, 2021

Gain key clinical insights fast, with this short slideset from CCO on treatment options for patients with myeloma

Sarah A. Holstein, MD, PhD person default David M. Kaufman, MD Released: July 7, 2020

Gain key clinical insights quickly with this short slideset from CCO on CAR T-cell therapy for hematologic malignancies.

Michael R. Bishop, MD Daniel J. DeAngelo, MD, PhD Noopur Raje, MD Released: June 30, 2020

Downloadable slides with expert analysis of treatment strategies for heavily pretreated relapsed/refractory myeloma from Clinical Care Options.

Released: June 25, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?